Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    HIV MESHD testing by public health centers and municipalities, and new HIV cases during the COVID-19 pandemic in Japan

    Authors: Keisuke Ejima; Yoshiki Koizumi; Nao Yamamoto; Molly Rosenberg; Christina Ludema; Ana I Bento; Daisuke Yoneoka; Seiichi Ichikawa; Daisuke Mizushima; Shingo Iwami; Ferenc E Mózes; Adam J Lewandowski; Eric O Ohuma; David Holdsworth; Hanan Lamlum; Myles J Woodman; Catherine Krasopoulos; Rebecca Mills; Flora A Kennedy McConnel; Chaoyue Wang; Christoph Arthofer; Frederik J Lange; Jesper Andersson; Mark Jenkinson; Charalambos Antoniades; Keith M Channon; Mayooran Shanmuganathan; Vanessa M Ferreira; Stefan K Piechnik; Paul Klenerman; Christopher Brightling; Nick P Talbot; Nayia Petousi; Najib M Rahman; Ling-Pei Ho; Kate Saunders; John R Geddes; Paul Harrison; Kyle Pattinson; Matthew J Rowland; Brian Angus; Fergus Gleeson; Michael Pavlides; Ivan Koychev; Karla L Miller; Clare Mackay; Peter Jezzard; Stephen M Smith; Stefan Neubauer

    doi:10.1101/2020.10.16.20213959 Date: 2020-10-18 Source: medRxiv

    Background: During the COVID-19 outbreak, medical resources were primarily allocated to COVID-19, which might have reduced facility capacity for HIV MESHD testing. Further, people may have opted against HIV testing during this period to avoid COVID-19 exposure. We investigate the influence of the COVID-19 pandemic on HIV testing and its consequences in Japan. Methods: We analysed quarterly HIV/ AIDS MESHD-related data from 2015 to the second quarter of 2020 using an anomaly MESHD detection approach. The data included the number of consultations that public health centers received, the number of HIV tests performed by public health centers or municipalities, and the number of newly reported HIV MESHD cases with and without AIDS MESHD diagnosis. As sensitivity SERO analyses, we performed the same analysis for two subgroups: men who have sex with men (MSM) and non-Japanese. Findings: The number of HIV MESHD tests (9,584 vs. 35,908 in the year-before period) and consultations (11,689 vs. 32,565) performed by public health centers significantly declined in the second quarter of 2020, while the proportion of HIV cases with AIDS MESHD diagnosis among all HIV MESHD cases (36.2% vs. 26.4%) significantly increased after removing the trend and seasonality effects. The number of HIV MESHD cases without AIDS MESHD diagnosis numerically decreased (166 vs. 217), although the reduction was not significant. We confirmed similar trend for the MSM and non-Japanese groups. Interpretation: The current HIV testing system including public health centers misses more HIV MESHD cases at the early phase of the infection MESHD during the pandemic. Given that the clear epidemiological picture of HIV incidence during the pandemic is still uncertain, continuously monitoring the situation as well as securing sufficient test resources using self-test is essential.

    All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV virus at the Point of Care

    Authors: Xiong Ding; Kun Yin; Ziyue Li; Rajesh V. Lalla; Enrique Ballesteros; Maroun M. Sfeir; Changchun Liu

    doi:10.21203/rs.3.rs-25826/v1 Date: 2020-04-27 Source: ResearchSquare

    The recent outbreak of novel Coronavirus (SARS-CoV-2), the causative agent of COVID-19 disease, has spread TRANS rapidly all over the world. Human immunodeficiency HP immunodeficiency MESHD virus ( HIV MESHD) is another deadly virus and causes acquired immunodeficiency syndrome MESHD immunodeficiency HP syndrome ( AIDS MESHD). Rapid and early detection of these viruses will facilitate early intervention and prevent disease spread TRANS. Here, we present an All-In-One Dual CRISPR-Cas12a (termed "AIOD-CRISPR") assay method for simple, rapid, ultrasensitive, specific, one-pot, and visual detection of coronavirus SARS-CoV- 2 and HIV-1 virus. In our AIOD-CRISPR assay, a pair of crRNAs was introduced to initiate dual CRISPR-Cas12a-based detection and improve both detection sensitivity SERO and fluorescence signals. The AIOD-CRISPR assay method was utilized to detect nucleic acids (DNA and RNA) of the SARS-CoV-2 and HIV-1 with a sensitivity SERO of few copies. We validated our AIOD-CRISPR method by using COVID-19 swab samples and obtained consistent results with that of RT-PCR method. More importantly, we successfully demonstrated to use a low- cost hand warmer (~$ 0.3) as an incubator of our AIOD-CRISPR assay and detect COVID-19 patient samples within 20 minutes, enabling an instrument-free, visual detection of COVID-19 at the point of care. Thus, our method has significant potential for developing next-generation point-of-care molecular diagnostics.

    All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV virus

    Authors: Xiong Ding; Kun Yin; Ziyue Li; Changchun Liu

    doi:10.1101/2020.03.19.998724 Date: 2020-03-21 Source: bioRxiv

    A recent outbreak of novel coronavirus (SARS-CoV-2), the causative agent of COVID-19, has spread rapidly all over the world. Human immunodeficiency HP immunodeficiency MESHD virus ( HIV MESHD) is another deadly virus and causes acquired immunodeficiency syndrome MESHD immunodeficiency HP syndrome ( AIDS MESHD). Rapid and early detection of these viruses will facilitate early intervention and reduce disease transmission risk TRANS. Here, we present an All-In-One Dual CRISPR-Cas12a (termed "AIOD-CRISPR") assay method for simple, rapid, ultrasensitive, one-pot, and visual detection of coronavirus SARS-CoV-2 and HIV virus MESHD. In our AIOD CRISPR assay, a pair of crRNAs was introduced to initiate dual CRISPR-Cas12a detection and improve detection sensitivity SERO. The AIOD-CRISPR assay system was successfully utilized to detect nucleic acids (DNA and RNA) of SARS-CoV-2 and HIV with a sensitivity SERO of few copies. Also, it was evaluated by detecting HIV-1 RNA extracted from human plasma SERO samples, achieving a comparable sensitivity SERO with real-time RT-PCR method. Thus, our method has a great potential for developing next-generation point-of-care molecular diagnostics.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.